Company Description
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders.
We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.
Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Our lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic, or PAC, which we are initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis, or ADP.
We are currently conducting Phase 2 trials evaluating ML-007C-MA for the treatment of schizophrenia and for the treatment of ADP, and expect topline results in the second half of 2026 and 2027 respectively.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 109 |
| CEO | Christopher A. Kroeger, M.D. |
Contact Details
Address: 800 Chesapeake Drive Redwood City, CA 94063 United States | |
| Phone | (617) 984-6300 |
| Website | maplightrx.com |
Stock Details
| Ticker Symbol | MPLT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001770069 |
| Employer ID | 83-2163243 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher A. Kroeger, M.D. | Chief Executive Officer and Director |
| Vishwas Setia | Chief Financial Officer |
| Erin Pennock Foff, M.D., Ph.D. | Chief Medical Officer |
| Jonathan Gillis | Chief Administrative and Accounting Officer |
| Anatol Kreitzer, Ph.D. | Chief Discovery Officer |
| James Lillie, Ph.D. | Chief Scientific Officer |
| Kristopher L. Hanson | General Counsel |
| Timothy Garnett, M.B.B.S. | Director |
| Nanna Lüneborg, Ph.D. | Director |
| Robert Malenka, M.D., Ph.D | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 19, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 22, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jul 30, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jul 28, 2025 | D | Notice of Exempt Offering of Securities |
| May 10, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 12, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Mar 8, 2024 | DRS | [Cover] Draft Registration Statement |
| Nov 3, 2023 | D/A | Filing |
| Jul 19, 2023 | D | Notice of Exempt Offering of Securities |
| Nov 10, 2022 | D | Notice of Exempt Offering of Securities |